Trademark: 87756187
Word
BRAFTOVI ENCORAFENIB CAPSULES
Status Date
Tuesday, December 11, 2018
Registration Number
5625743
Registration Date
Tuesday, December 11, 2018
Filing Date
Tuesday, January 16, 2018
Published for Opposition
Tuesday, September 25, 2018
5 [ Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use;] Pharmaceutical products for the [ prevention and ] treatment of cancer [ and tumors; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma ]
The mark consists of three sphere designs diagonally above the word "BRAFTOVI" over the words encorafenib capsules, wherein the term encorafenib is in parentheses.
In the statement, Column 2, lines 4-22, " Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; for the prevention and and tumors; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma " is deleted.
Color is not claimed as a feature of the mark.
"CAPSULES" AND "ENCORAFENIB"
Jan 2, 2024
Teas Section 8 & 15 Received
Dec 11, 2023
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Nov 16, 2020
Amendment Under Section 7 - Processed
Nov 16, 2020
Case Assigned To Post Registration Paralegal
Jul 16, 2020
Teas Section 7 Request Received
Jun 4, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 4, 2020
Teas Change Of Correspondence Received
Jun 4, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 4, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 4, 2020
Teas Change Of Owner Address Received
Dec 11, 2018
Registered-Principal Register
Sep 25, 2018
Official Gazette Publication Confirmation E-Mailed
Sep 25, 2018
Published For Opposition
Sep 5, 2018
Notification Of Notice Of Publication E-Mailed
Aug 21, 2018
Assigned To Lie
Aug 9, 2018
Approved For Pub - Principal Register
Aug 9, 2018
Examiner's Amendment Entered
Aug 9, 2018
Notification Of Examiners Amendment E-Mailed
Aug 9, 2018
Examiners Amendment E-Mailed
Aug 9, 2018
Examiners Amendment -Written
Jul 13, 2018
Notice Of Acceptance Of Amendment To Allege Use E-Mailed
Jul 12, 2018
Use Amendment Accepted
Jul 11, 2018
Amendment To Use Processing Complete
Jul 11, 2018
Use Amendment Filed
Jul 10, 2018
Teas Amendment Of Use Received
May 3, 2018
Notification Of Non-Final Action E-Mailed
May 3, 2018
Non-Final Action E-Mailed
May 3, 2018
Non-Final Action Written
Apr 26, 2018
Assigned To Examiner
Jan 30, 2018
Notice Of Design Search Code E-Mailed
Jan 28, 2018
New Application Office Supplied Data Entered
Jan 19, 2018
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
